# TAZPOWER: Study Design of a Randomized, Double-Blind, Placebo-Controlled Crossover and Extension Trial of Elamipretide in **Subjects with Barth Syndrome and Baseline Characteristics**

# Hilary Vernon, MD, PhD<sup>1</sup>; William Reid Thompson III, MD<sup>2</sup>; Anthony Aiudi, PharmD<sup>3</sup>; Jim Carr, PharmD<sup>3</sup>; Jim Carr, PharmD<sup>3</sup>; John J. Jones, PharmD<sup>3</sup>; John J. Jones, PharmD<sup>3</sup>; Jim Carr, PharmD<sup></sup>


<sup>1</sup>McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; <sup>2</sup>Division of Pediatric Cardiology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD; <sup>2</sup>Division of Pediatric Cardiology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD; <sup>2</sup>Division of Pediatric Cardiology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD; <sup>4</sup>Division of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD; <sup>4</sup>Division of Pediatric Cardiology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD; <sup>4</sup>Division of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD; <sup>4</sup>Division of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD; <sup>4</sup>Division of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD; <sup>4</sup>Division of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD; <sup>4</sup>Division of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD; <sup>4</sup>Division of Pediatrics, Baltimore, MD; <sup>4</sup>Division of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD; <sup>4</sup>Division of Pediatrics, Baltimore, Baltimore, Baltimore, MD; <sup>4</sup>Division of Pediatrics, Baltimore, Baltimo <sup>3</sup>Stealth BioTherapeutics, Newton, MA; <sup>4</sup>Department of Physical Therapy, Kennedy Krieger Institute, Baltimore, MD

# INTRODUCTION

- Barth syndrome (BTHS) is a rare, X-linked infantile-onset disease caused by defects in the TAZ gene that encodes Tafazzin, a transacylase that is responsible for the final remodeling step from immature cardiolipin (MLCL) to mature cardiolipin (L4-CL)
- Tafazzin deficiency results in abnormal MLCL:L4-CL ratio
- Mature CL is critical to normal mitochondrial function and ATP generation • Clinical presentation of BTHS is typically characterized by cardiomyopathy, skeletal myopathy, neutropenia, and growth abnormalities
- Increasing MLCL:L4-CL is correlated with increasing left ventricular mass, and inversely correlated with the distance walked on the 6MWT
- TAZPOWER is the first clinical trial to evaluate the efficacy/safety of a therapeutic agent in BTHS patients

### OBJECTIVE

- To measure efficacy through functional and patient-reported outcome assessments, exploratory biomarkers, and safety/tolerability through adverse events (AEs), clinical data, and laboratory tests
- Subgroup analyses will be conducted to evaluate the potential clinical impact of differences in the immature CL to mature CL (MLCL:L4-CL) ratio



### Key Inclusion Criteria

• Patients  $\geq$ 12 years of age were required to have genetically confirmed BTHS, to be ambulatory but impaired as assessed by the 6MWT, and on stable medications

# Key Exclusion Criteria

• Patients were excluded if they had been hospitalized within 30 days, had uncontrolled hypertension, a history of heart transplantation, or implantation of a cardioverter defibrillator within 3 months or expected implantation during the study

### Baseline Assessments

- Functional assessments conducted at baseline included:
  - <u>6-Minute Walk Test (6MWT)</u> is a functional-based test of exercise performance that measures the distance (meters) an individual is able to walk over a total of 6 minutes
  - Five Times Sit-to-Stand Test (5XSST) assesses functional lower extremity strength, transitional movements, balance, and fall risk by measuring time (seconds) it takes a patient to stand from and return to a seated position, repeated 5 times
  - **SWAY Application Balance Assessment** provides an average of the deflections reported during 5 stances and ranges from 0 to 100, with higher scores indicating better balance
- Hand held dynamometry (HHD) is an assessment of muscle strength (newtons) of both knee extensors reporting an average of 2 attempts for each extremity
- **Echocardiogram** documenting cardiac structural and functional parameters • Patient-/caregiver-/clinician-reported outcome assessments included:
- Global Impression of Symptom Severity and Change Scales rate overall assessment of symptoms related to BTHS on a 5-point scaled question scored 0 to 4 (0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Very Severe) and Global Impression of Change scales rate changes in symptoms related to BTHS on a 7-point scaled question score -3 to 3 (-3=Very much Worse; -2=Moderately Worse; -1=A Little Worse, 0=No Change, 1=A Little Better, 2=Moderately Better, 3=Very much Better)
  - CGI Clinician Global Impression of Symptom Severity and Change
  - **PGI** Patient Global Impression of Symptom Severity and Change
  - CaGI Caregiver Global Impression of Symptom Severity and Change
- BarTH Syndrome Symptom Assessment (BTHS-SA), which is an age-appropriate, daily patient-reported outcome that was created, in accordance with FDA guidance on Patient-Reported Outcome Measures, to assess the severity of the most common symptoms of BTHS using a 5-point scale (1=Not at All, 2=Mild, 3=Moderate, 4=Severe, 5=Very Severe). The BTHS-SA scores are the average of the daily scores over the 7 consecutive days immediately prior to a visit
- **BTHS-SA Total Fatigue** score, a pre-specified fatigue subscale that assessed a subset of 3 symptoms: tiredness at rest, tiredness during activities, and muscle weakness during activities
- **PROMIS Short Form Fatigue** used to evaluate self-reported symptoms of tiredness to debilitating sense of exhaustion

- **PROMIS Fatigue Short Form 8a** consists of 8 questions and has a possible raw score from 8 to 40. Each question is scored 1 to 5 (1=Not at All/Never, 2=A Little Bit/Rarely, 3=Somewhat/Sometimes, 4=Quite a Bit/Often, and 5=Very Much/Always)
- **PROMIS Pediatric Fatigue Short Form 10a** consists of 10 questions and has a possible raw score from 0 to 40. Each question is scored 0 to 4 (0=Never, 1=Almost Never, 2=Sometimes, 3=Often, 4=Almost Always)
- Both the PROMIS Fatigue Short Form 8a and PROMIS Pediatric Fatigue Short Form 10a raw scores are converted to T-scores (with a T = 50 indicating average function compared to the reference population and a standard deviation of 10). T-scores from both assessments were reported together and considered a single secondary endpoint irrespective of age group
- Exploratory biomarkers MLCL:L4-CL ratio
- Patient Perception of Change (PPC) and Caregiver Perception of Change (CPC) Video Assessments
- A prospectively defined video protocol to collect evidence of clinical meaningfulness to patients Subgroup Analyses
- Subgroup analyses based on screening MLCL:L4-CL ratio will be conducted with subgroups delineated by the median MLCL:L4-CL ratio

# RESULTS

### Patient Demographics

Table 1. Patient Demographics (N=12)

Table 1. Patient Demographics (N=12)					
Demographic Variable	Total Population Mean (Range)	Pediatric 12 to 17 years Mean (Range)	Adult ≥18 years Mean (Range)		
Age (years)	19.5 (12-35)	14.9 (12-17)	28.8 (21-35)		
Male (n)	12	8	4		
Race (n) White Multiracial	11 1	7 1	4 0		
Ethnicity (n) Not Hispanic or Latino Hispanic or Latino	12 0	8 0	4 0		
Height (cm)	167.3 (150.4-187.7)	160.2 (150.4-180.0)	181.5 (172.7-187.7)		
Weight (kg)	50.84 (31.4-85.9)	41.3 (31.4-74.5)	69.9 (63.8-85.9)		
BMI (kg/m²)	17.6 (13.6-24.4)	15.8 (13.6-23.0)	21.2 (18.7-24.4)		

# **Baseline Patient Characteristics**

- Vital signs, including ECG parameters, were within normal limits
- Average laboratory values (eGRF, ALT, and AST) were within normal limits at baseline, indicating normal liver and renal function

NOTE: 2 pediatric patients had ALT levels of 30 U/L and 33 U/L, respectively (reference range 9-24 U/L)

# Baseline Comorbid Medical Diagnoses and Concomitant Medications

- Most commonly reported comorbid medical diagnoses reported in ≥50% of patients at
- baseline included cardiomyopathy (66.6%), neutropenia (58.3%), and hypotonia (50%) • At baseline, the % ejection fraction was within normal limits for all patients
- 91.6% (n=11) patients reported taking at least 1 concomitant prescription medication at baseline

# **Table 2.** Selected Concomitant Prescription


Indication for Use	Prescription Medication	Number of Patients Reporting Use at Baseline
Cardioprotection:	ACE inhibitor (various)	5
Cardiomyopathy/Heart Failure	Digoxin	4
	Carvedilol/Metoprolol	4
	Losartan	1
	Spironolactone	1
Neutropenia/Infection Prevention	Filgrastim	7
	TMP/SMX	1
	Amoxicillin	1
BTHS "Tonic"/ Mitochondrial Function	Citrulline	4
	Arginine	2
	CoQ10	2
	Levocarnitine	1

Medications at Baseline				
	Number of Patie			

### Baseline Functional Assessments

- (Figure 2)
- subjects (659±62 m)

### Figure 2. Baseline Functional Assessments (N=12)\*





\*n=11 for the 5XSST (1 participant could not attempt the 5XSST due to leg weakness)

Table 3. Patient-/Caregiver-/Clinician-reported Outcome Assessments (N=12)				
Outcome Assessment	Average Score	Range (Min-Max)		
BTHS-SA Total Fatigue	8.0	5.9-10		
Global Impression of Symptom Severity scale				
CGI	2.4	2-3		
PGI	2.8	2-4		
CaGI	2.3	1-3		
PROMIS Fatigue T-Score	63.6	52.5-74.4*		

\*T-score of 50=average fatigue of the general US population

Table 4. Individual Patient Screening MLCL:L4-CL Ratio*				
Subject ID	Screening Ratio		Subject ID	Screening Ratio
101-001	23.0		101-008	35.4
101-003	32.7		101-010	22.8
101-004	15.6		101-013	11.2
101-005	29.4		101-014	18.4
101-006	16.2		101-015	2.3
101-007	4.4		101-016	6.7

Table 4. Individual Patient Screening MLCL:L4-CL Ratio*					
Subject ID	Screening Ratio	Subject ID		Screening	Ratio
101-001	23.0	101-(	800	35.4	
101-003	32.7	101-0	010	22.8	
101-004	15.6	101-0	013	11.2	
101-005	29.4	101-0	014	18.4	
101-006	16.2	101-0	015	2.3	
101-007	4.4	101-0	016	6.7	

\*Median 17.3

# CONCLUSIONS

- of patients with more severe medical histories
- unaddressed by current therapy

**Disclosures:** The authors declare no conflict of interest Study Funding: Trial funded by Stealth BioTherapeutics, Newton, MA Acknowledgements: Medical writing assistance was provided by James A. Shiffer, RPh, Write On Time Medical Communications, LLC

Baseline functional assessments demonstrated impairment in the BTHS patient population

- Average 6MWT score was significantly lower than the average reported in healthy


- Average SWAY balance score was lower than reported in healthy subjects (86.9  $\pm$ 14.37) - Average 5XSST score was higher that the average reported in healthy subjects (11.4 sec)

Average:

72.0 score

Range (min-max):

42.8-92.2 score



10 A A 16



**HHD Knee Extensor** Strength Average: 133.1 Newtons Range (min-max): 79.6-159.2 Newtons

Average:

12.7 seconds

Range (min-max):

7.9-16.37 seconds

Patients enrolled in the TAZPOWER clinical trial have comorbidities that are well managed with current standards for cardiac and hematologic care

The inclusion and exclusion criteria for the TAZPOWER trial precluded participation

 Functional test results, Global Impression questionnaire results, and exploratory biomarkers findings indicate an additional disease burden that remains

• TAZPOWER is the first clinical trial specifically designed to evaluate a therapeutic agent, elamipretide, in the treatment of patients with BTHS



